Nifty
:
18537.25
Sensex
:
62403.63
24.50 (0.13%)
109.99 (0.18%)
Nifty
Sensex
:
:
18537.25
62403.63
24.50 (0.13%)
109.99 (0.18%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
50/99

BSE: 532296 | NSE: GLENMARK

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 12,037.29
  • 14.47
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 14,296.13
  • 0.59%
  • 1.26

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 1.28%
  • 16.47%
  • FII
  • DII
  • Others
  • 23.14%
  • 10.46%
  • 2.00%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.49
  • 6.28
  • 4.96

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.62
  • 7.51
  • 6.44

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.27
  • 3.22
  • 6.66

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.38
  • 14.86
  • 14.26

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.03
  • 2.21
  • 1.78

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.20
  • 8.95
  • 7.72

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Net Sales
3,375.25
3,147.45
7.24%
2,777.29
2,964.89
-6.33%
3,019.15
2,859.90
5.57%
3,173.41
2,786.76
13.87%
Expenses
2,753.69
2,557.28
7.68%
2,345.69
2,391.32
-1.91%
2,555.75
2,336.47
9.39%
2,480.26
2,256.69
9.91%
EBITDA
621.56
590.17
5.32%
431.60
573.58
-24.75%
463.40
523.43
-11.47%
693.15
530.07
30.77%
EBIDTM
18.42%
18.75%
15.54%
19.35%
15.35%
18.30%
21.84%
19.02%
Other Income
97.43
-13.07
-
183.16
58.65
212.29%
107.20
8.49
1,162.66%
13.89
15.09
-7.95%
Interest
83.07
68.95
20.48%
59.99
75.60
-20.65%
86.85
83.33
4.22%
66.70
95.41
-30.09%
Depreciation
155.71
123.19
26.40%
146.75
113.07
29.79%
131.52
111.07
18.41%
118.93
115.20
3.24%
PBT
480.21
384.96
24.74%
408.01
443.55
-8.01%
269.69
337.51
-20.09%
343.04
347.97
-1.42%
Tax
201.54
110.16
82.95%
196.91
137.03
43.70%
97.13
103.65
-6.29%
103.29
99.79
3.51%
PAT
278.67
274.81
1.40%
211.11
306.53
-31.13%
172.57
233.87
-26.21%
239.75
248.18
-3.40%
PATM
8.26%
8.73%
7.60%
10.34%
5.72%
8.18%
7.55%
8.91%
EPS
9.23
9.13
1.10%
6.82
10.86
-37.20%
5.51
8.29
-33.53%
7.86
8.79
-10.58%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
12,345.10
12,304.90
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
Net Sales Growth
4.98%
12.44%
2.85%
7.86%
8.72%
-0.05%
20.07%
13.18%
12.38%
19.64%
 
Cost Of Goods Sold
4,281.54
4,312.08
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
Gross Profit
8,063.56
7,992.82
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
GP Margin
65.32%
64.96%
66.92%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
Total Expenditure
10,135.39
9,984.60
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
Power & Fuel Cost
-
200.64
164.67
173.69
165.25
137.47
127.02
120.47
109.11
93.50
80.13
% Of Sales
-
1.63%
1.50%
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
Employee Cost
-
2,447.42
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
% Of Sales
-
19.89%
21.42%
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
Manufacturing Exp.
-
784.62
638.74
669.50
725.16
648.59
546.75
956.59
1,323.66
336.59
272.53
% Of Sales
-
6.38%
5.84%
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
General & Admin Exp.
-
1,264.86
1,027.60
1,168.32
891.10
526.29
1,022.89
491.20
253.29
859.67
678.94
% Of Sales
-
10.28%
9.39%
10.98%
9.03%
5.80%
11.27%
6.50%
3.79%
14.46%
13.66%
Selling & Distn. Exp.
-
896.31
943.21
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
524.25
521.00
% Of Sales
-
7.28%
8.62%
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
Miscellaneous Exp.
-
78.68
121.44
47.19
33.29
314.55
88.52
38.82
38.48
228.40
521.00
% Of Sales
-
0.64%
1.11%
0.44%
0.34%
3.47%
0.97%
0.51%
0.58%
3.84%
0.68%
EBITDA
2,209.71
2,320.30
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
EBITDA Margin
17.90%
18.86%
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
Other Income
401.68
166.67
50.22
159.60
208.14
91.40
37.37
20.00
6.88
11.48
10.75
Interest
296.61
298.10
353.11
377.32
334.58
285.57
237.32
178.88
190.15
188.59
160.01
Depreciation
552.91
486.71
443.55
417.17
325.90
301.88
264.37
234.28
300.41
216.79
127.01
PBT
1,500.95
1,702.16
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
Tax
598.87
447.60
412.39
320.11
375.64
315.46
382.68
300.94
334.07
151.27
110.72
Tax Rate
39.90%
31.06%
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
PAT
902.10
941.65
970.04
775.97
924.98
803.78
1,108.80
743.23
209.54
542.27
620.03
PAT before Minority Interest
830.46
993.65
970.09
775.97
924.99
803.87
1,108.75
743.04
209.47
545.60
628.29
Minority Interest
-71.64
-52.00
-0.05
0.00
-0.01
-0.09
0.05
0.19
0.07
-3.33
-8.26
PAT Margin
7.31%
7.65%
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
PAT Growth
-15.17%
-2.93%
25.01%
-16.11%
15.08%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
 
EPS
31.97
33.37
34.37
27.50
32.78
28.48
39.29
26.34
7.43
19.22
21.97

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
9,086.65
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
27.13
27.12
27.09
Total Reserves
9,042.13
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
Non-Current Liabilities
1,269.61
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
2,428.66
1,920.30
Unsecured Loans
2,571.74
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
4,689.43
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
Trade Payables
2,288.66
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
Other Current Liabilities
1,446.27
885.78
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
973.31
763.41
Short Term Borrowings
370.00
513.01
442.60
303.02
295.04
187.19
787.42
347.60
353.32
367.82
Short Term Provisions
584.50
564.45
555.91
484.11
432.46
262.95
134.03
216.78
259.95
33.22
Total Liabilities
15,397.16
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
Net Block
5,887.25
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
Gross Block
10,213.47
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
Accumulated Depreciation
4,326.23
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
Non Current Assets
7,114.82
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
Capital Work in Progress
1,009.87
1,381.67
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
206.24
422.31
Non Current Investment
49.62
24.63
24.59
29.66
14.66
15.69
17.20
17.12
0.00
0.00
Long Term Loans & Adv.
161.38
146.29
123.97
94.36
119.78
98.94
69.99
468.16
33.39
36.52
Other Non Current Assets
6.70
27.89
26.49
15.80
0.56
0.13
0.16
0.27
20.33
22.00
Current Assets
8,282.35
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,499.83
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
Sundry Debtors
3,101.14
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
Cash & Bank
1,411.52
1,139.16
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
800.67
607.31
Other Current Assets
1,269.87
671.05
603.30
765.22
1,391.61
1,273.61
986.77
774.38
872.81
635.91
Short Term Loans & Adv.
537.12
700.49
544.48
547.18
580.83
590.22
594.89
742.94
768.44
540.03
Net Current Assets
3,592.92
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
Total Assets
15,397.17
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
1,108.65
1,131.21
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
853.73
647.93
PBT
1,441.25
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
Adjustment
787.11
644.82
636.23
329.83
571.28
726.56
391.03
522.76
709.78
342.45
Changes in Working Capital
-561.26
-385.84
127.06
136.34
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
Cash after chg. in Working capital
1,667.09
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-558.44
-510.24
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-333.28
-675.24
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
Net Fixed Assets
-155.36
-184.89
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
Net Investments
-1,569.44
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
Others
1,391.52
1,785.67
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
Cash from Financing Activity
-520.49
-441.78
-444.66
-738.74
-468.50
543.15
698.60
199.22
-98.02
195.24
Net Cash Inflow / Outflow
254.88
14.20
164.23
-113.56
166.21
488.24
163.27
140.86
387.61
379.11
Opening Cash & Equivalents
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
Closing Cash & Equivalent
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
321.45
249.60
214.65
198.27
182.62
159.16
128.59
65.74
109.99
102.01
ROA
6.74%
7.11%
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
ROE
12.33%
14.81%
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
ROCE
14.19%
15.30%
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
Fixed Asset Turnover
2.94
2.97
1.44
1.66
1.80
2.03
1.96
1.90
1.83
1.79
Receivable days
37.24
36.01
78.95
83.73
94.95
97.29
119.39
125.97
115.37
104.99
Inventory Days
31.35
31.90
75.25
79.22
83.59
73.65
67.68
59.42
53.99
59.39
Payable days
191.57
219.98
98.44
97.43
96.28
101.59
117.03
95.22
83.15
68.48
Cash Conversion Cycle
-122.98
-152.06
55.77
65.53
82.26
69.35
70.04
90.17
86.21
95.91
Total Debt/Equity
0.40
0.67
0.80
0.80
0.90
1.05
1.10
2.13
1.10
1.00
Interest Cover
5.83
4.92
3.90
4.89
4.92
7.28
6.84
3.86
4.70
5.62

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • USFDA issues warning letter to Glenmark Pharmaceuticals’ Goa facility
    24th Nov 2022, 10:20 AM

    The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility

    Read More
  • Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for Axitinib Tablets
    22nd Nov 2022, 09:22 AM

    Glenmark’s current portfolio consists of 177 products authorized for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA

    Read More
  • Glenmark Pharmaceuticals reports marginal rise in Q2 consolidated net profit
    12th Nov 2022, 14:27 PM

    Total consolidated income of the company increased by 10.79% to Rs 3,472.68 crore for Q2FY23

    Read More
  • Glenmark Pharma - Quarterly Results
    11th Nov 2022, 18:47 PM

    Read More
  • Glenmark Pharmaceuticals gets USFDA’s nod for Sodium Phenylbutyrate Tablets
    2nd Nov 2022, 11:47 AM

    Glenmark’s current portfolio consists of 177 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the USFDA

    Read More
  • Glenmark Pharma’s arm launches Fingolimod Capsules in US
    1st Nov 2022, 09:37 AM

    Glenmark’s current portfolio consists of 176 products authorized for distribution in the U.S. marketplace

    Read More
  • Glenmark becomes first company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination
    20th Oct 2022, 09:28 AM

    Marketed under the brand name Zita D; it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg)

    Read More
  • Glenmark becomes first company to launch Lobeglitazone in India for uncontrolled type 2 diabetes in adults
    6th Oct 2022, 09:20 AM

    The results of this trial have shown a faster and improved glycemic control with Lobeglitazone

    Read More
  • Glenmark Pharma’s arm launches Ryaltris seasonal allergic rhinitis nasal spray in US
    1st Sep 2022, 11:14 AM

    The onset of action for nasal symptom relief occurs within 15 minutes of a patient taking the first dose

    Read More
  • Glenmark looking at flat to low single-digit growth in US for FY23
    23rd Aug 2022, 15:17 PM

    The company's North American business, including the US, recorded a revenue of Rs 662.8 crore in April-June 2022

    Read More
  • Glenmark Pharma’s arm recalls 72,000 units of BP lowering drug in US markets
    22nd Aug 2022, 09:16 AM

    The USFDA stated that Glenmark initiated the Class II nationwide (US) recall on June 29 this year

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.